Skip to main content
. Author manuscript; available in PMC: 2023 Oct 16.
Published in final edited form as: Acc Mater Res. 2022 Jan 12;3(2):134–148. doi: 10.1021/accountsmr.1c00177

Figure 6:

Figure 6:

A) The scheme represents anti-spike, anti-membrane and anti-envelope antibody attached gold nanoparticles-based detection of viral particles. B) The photograph shows colorimetric test results for COVID-19 positive and negative clinical samples. Reproduced with permission from Ref (21). Copyright 2020 American Chemical Society. C) Schematics shows gold nanoparticle-CRISPR/Cas12a system-based diagnosis of clinical sample. D) Assessment of clinical sample detection using gold nanoparticle-CRISPR/Cas12a system-based. Reproduced with permission from Ref (22). Copyright 2021 American Chemical Society. E-F) Performance of gold nanoparticle based LFA for human serum sample from clinical sample, E) without COVID-19 infection and F) with COVID-19 infected patients. Reproduced with permission from Ref (27). Copyright 2020 American Chemical Society.